Cholestatic liver diseases: An era of emerging therapies

Recently the field of cholestasis has expanded enormously reflecting an improved understanding of the molecular mechanisms underlying bile secretion and its perturbation in chronic cholestatic disease. Novel anti-cholestatic therapeutic options have been developed for patients not favorably respondi...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of clinical cases Vol. 7; no. 13; pp. 1571 - 1581
Main Authors Samant, Hrishikesh, Manatsathit, Wuttiporn, Dies, David, Shokouh-Amiri, Hosein, Zibari, Gazi, Boktor, Moheb, Alexander, Jonathan Steve
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 06.07.2019
Subjects
Minireviews
Bile acids
Cholestatic liver disease
Drug therapy
Nuclear receptor agonists
Online AccessGet full text

Cover

More Information
Summary:Recently the field of cholestasis has expanded enormously reflecting an improved understanding of the molecular mechanisms underlying bile secretion and its perturbation in chronic cholestatic disease. Novel anti-cholestatic therapeutic options have been developed for patients not favorably responding to ursodeoxycholic acid (UDCA), the current standard treatment for cholestatic liver disease. Important novel treatment targets now also include nuclear receptors involved in bile acid (BA) homoeostasis like farnesoid X receptor and G protein-coupled receptors ., the G-protein-coupled BA receptor "transmembrane G coupled receptor 5". Fibroblast growth factor-19 and enterohepatic BA transporters also deserve attention as additional drug targets as does the potential treatment agent norUDCA. In this review, we discuss recent and future promising therapeutic agents and their potential molecular mechanisms in cholestatic liver disorders.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Author contributions: Samant H did literature search and wrote the paper. Manatsathit W, Dies D, Shokouh-Amiri H, Zibari G and Boktor M gave inputs and reviewed it. Alexander JS did critical edit, figures construction and finalize the article.
Corresponding author: Jonathan Steve Alexander, FACG, PhD, Professor, Department of Molecular and Cellular Physiology, Louisiana State University, School of Medicine, 1501 Kings Highway, Shreveport, LA 71103, United States. jalexa@lsuhsc.edu
Telephone: +1-318-6754151 Fax: +1-318-6754156
ISSN:2307-8960
2307-8960
DOI:10.12998/wjcc.v7.i13.1571